SUNNYVALE, Calif.--Amersham Pharmacia Biotech, the life sciences division of Nycomed Amersham, announced that the new version of Phred, the sequencing analysis program used by high-throughput DNA sequencing facilities, has been recalibrated for data produced by its MegaBace 1000 DNA sequencer. So far, it is the only capillary sequencer to be validated with the new Phred version, which is being released by the University of Washington.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.